Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Gene Implicated in Chronic Kidney Disease


Duke University Medical Center researchers have discovered a gene responsible for one form of chronic kidney disease. The disease, called familial focal segmental glomerulosclerosis (FSGS), can lead to complete kidney failure and affects 20 percent of patients on dialysis. The finding could lead to more effective treatments, according to the researchers.

By examining the genetic makeup of one large, multi-generational family with a dominant form of FSGS, the researchers linked a mutant form of the gene called Transient Receptor Potential Cation Channel 6 (TRPC6) to the disease. What’s more, because the gene differs in function from those earlier implicated in FSGS, the finding represents a novel mechanism of kidney damage, said Michelle Winn, M.D., a kidney specialist and geneticist at the Duke Center for Human Genetics and lead author of the study.

Drugs that target the ion channel might offer an effective treatment to slow or prevent scarring of the kidney, the primary manifestation of the disease seen in patients, the researchers said. Such channels are pore-like proteins in the membranes of cells thought to control the flow of calcium.

"This gene represents the first ion channel to be associated with FSGS," Winn said. "It’s a new mechanism for kidney disease, which may allow us to advance on new treatments as ion channels are known to be amenable to drug therapy."

Winn, along with senior authors Jeffery Vance, M.D. and Paul Rosenberg, M.D., also of Duke, published their findings May 5, 2005, in Science Express, the early online version of the journal Science.

In the United States, the prevalence of FSGS is increasing yearly, with a particularly high incidence among African-Americans, Winn said. The disease attacks tiny filtering units within the kidney called glomeruli -- leading to scarring, or hardening, of this filter. Symptoms of the disease include high blood pressure, an excess of protein in the urine, and insufficient elimination of wastes by the kidneys.

Drug therapies for FSGS are limited and non-specific, Winn added. Therefore, the kidney damage forces many patients to rely on hemodialysis, a procedure in which a patient’s blood is fed through a machine. A filter in the dialysis machine removes wastes and extra fluids and returns purified blood to the body. Most dialysis patients undergo the procedure at a clinic three times a week for several hours.

While the causes of FSGS remain unclear, earlier evidence had linked three other genes to FSGS or FSGS-like diseases. The previously identified genes serve in the formation of structural proteins that support the cell membrane. In 1999, the Duke team identified a region of the genome linked to FSGS in a large New Zealand family.

In the current study, the researchers narrowed that span to the single gene, TRPC6, by screening 106 members of the seven-generation, 600-member family, including individuals with and without the disease.

In this family, all members with FSGS carry a mutation in the TRPC6 gene, the team reported. Further study of the gene variant in kidney cell cultures found that the mutation enhances the activity of the channels in response to angiotensin II, a protein known to promote high blood pressure and kidney injury, Winn said.

While TRPC6 mutations have yet to be reported in other families with hereditary FSGS, the findings raise a number of questions about the role of the channels in kidney function.

The channels may also offer a new target for kidney disease treatment, according to the researchers.

"Because channels tend to be amenable to pharmacological manipulation, our study raises the possibility that TRPC6 may be a useful therapeutic target in chronic kidney disease," Winn said.

The researchers have begun a broader genomic screen of additional families from around the world to further examine genetic mechanisms in FSGS.

Collaborators on the study include Merry Kay Farrington, April Hawkins, Nikki Daskalakis, Shu Ying Kwan, Seth Ebersviller, Margaret Pericak-Vance, Tony Creazzo and James Burchette, of Duke; Peter Conlon, of Beaumont Hospital in Dublin, Ireland; and Kelvin Lynn, of Christchurch Hospital in Christchurch, New Zealand. The National Institutes of Health supported the research.

Kendall Morgan | EurekAlert!
Further information:

More articles from Life Sciences:

nachricht Signaling Pathways to the Nucleus
19.03.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht In monogamous species, a compatible partner is more important than an ornamented one
19.03.2018 | Max-Planck-Institut für Ornithologie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

A new kind of quantum bits in two dimensions

19.03.2018 | Physics and Astronomy

Scientists have a new way to gauge the growth of nanowires

19.03.2018 | Materials Sciences

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Science & Research
Overview of more VideoLinks >>>